Cara Therapeutic Ev To Sales Over Time
| CARA Stock | USD 0.30 0.01 3.45% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Cara Therapeutic Performance and Cara Therapeutic Correlation. Cara |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cara Therapeutic. If investors know Cara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cara Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.75) | Revenue Per Share 0.202 | Quarterly Revenue Growth (0.86) | Return On Assets (0.63) | Return On Equity (1.84) |
The market value of Cara Therapeutic is measured differently than its book value, which is the value of Cara that is recorded on the company's balance sheet. Investors also form their own opinion of Cara Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Cara Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cara Therapeutic's market value can be influenced by many factors that don't directly affect Cara Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cara Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cara Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cara Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Ev To Sales Analysis
Compare Cara Therapeutic and related stocks such as Zynerba Pharmaceuticals, 22nd Century Group, and Corbus Pharmaceuticals Ev To Sales Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XXII | 11.9538 | 11.9538 | 1.4 K | 12.0389 | 177 | 10.8257 | 5.7816 | 16.8427 | 11.7473 | 5.3987 | 10.855 | 15.5363 | 2.9177 | 0.5644 | 0.54 |
| CRBP | 61.0002 | 61.0002 | 61.0002 | 61.0002 | 61.0002 | 61.0002 | 174 | 121 | 60.4537 | 9.0358 | 9.9231 | 87.7231 | 87.7231 | 101 | 82.16 |
Cara Therapeutic and related stocks such as Zynerba Pharmaceuticals, 22nd Century Group, and Corbus Pharmaceuticals Ev To Sales description
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.My Equities
My Current Equities and Potential Positions
Check out Cara Therapeutic Performance and Cara Therapeutic Correlation. For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Cara Therapeutic technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.